Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2005 July-August;71(7-8) > Minerva Anestesiologica 2005 July-August;71(7-8):479-82

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ANESTESIOLOGICA

A Journal on Anesthesiology, Resuscitation, Analgesia and Intensive Care


Official Journal of the Italian Society of Anesthesiology, Analgesia, Resuscitation and Intensive Care
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,036


eTOC

 

REVIEWS  III MEETING OF PAIN SECTION OF SIAARTI
INTERNATIONAL J. J. BONICA MEMORIAL
Capo Calavà (Messina), September 20-23, 2004


Minerva Anestesiologica 2005 July-August;71(7-8):479-82

language: English

Scrambler therapy

Sabato A. F. 1, Marineo G. 2, Gatti A. 1

1 Anesthesiology and Resuscitation Unit Service of Physiopathology and Therapy of Pain Department of Emergency Tor Vergata University, Rome, Italy
2 Delta Research and Development Medical Bioengineering Research Centre Rome, Italy


FULL TEXT  


In neuropathies there are complex reactions that modify the homeostatic equilibrium of pain system. In such a context the Scrambler Therapy (ST5) interferes with pain signal transmission, by “mixing” a “non-pain” information into the nerve fibres.The aim of this study is to evaluate the effectiveness of ST5 in the treatment of neuropathic pain. The ST5 consists of a multiprocessor apparatus able to simulate 5 artificial neurons by the application of surface electrodes on skin pain areas. A total of 226 patients, all suffering from intense drug-resistant neuropathic pain, were recruited for this trial in 2004. Inclusion criteria: neuropathic pain, very high baseline visual analogue scale (VAS). Exclusion criteria: pacemaker users, neurolithic blocks or neurolesive pain control treatment. The treated neuropathic pain syndromes were: failed back surgery syndrome (FBSS), sciatic and lumbar painpost-herpetical (PHN), trigeminal neuralgia, post-surgery nerve lesion neuropathy, pudendal neuropathy, brachial plexus neuropathy, low back pain (LBP), others. The trial programme: 1 to 6 therapy sessions of 5 treatments, each one lasting 30 min. Pain intensity was evaluated using VAS before and after each treatment. The statistical significance of VAS was measured using the paired t-test. The total results show 80.09% of responders (pain relief >50%), 10.18% of partially responders (pain relief from 25% to 49%) and 9.73% of no responders (patients with pain relief <24% or VAS >3). The conclusion is draen that ST5 produced a statistically significant (P<0.0001) pain relief in all treated neuropathies.

top of page

Publication History

Cite this article as

Corresponding author e-mail